华邦健康：普瑞金已完成北交所上市辅导备案

Core Viewpoint - Huabang Health (002004) announced on September 9 that Pruijin has completed the listing guidance filing for the Beijing Stock Exchange, with further updates to be provided in subsequent announcements [1] Company Summary - Pruijin is a company focused on cell therapy CDMO (Contract Development and Manufacturing Organization) services, having established specialized platforms for nucleic acids, serum-free virus production, closed cell process development, and quality control testing [1] - The company offers a comprehensive range of services from drug discovery to IIT (Investigator Initiated Trials) non-registered clinical trials, and from sequence development to IND (Investigational New Drug) application [1]